Why the study?
The study was conducted to analyse the safety and efficacy of direct oral anticoagulants in real-world studies of atrial fibrillation patients.
Does the choice of DOAC affect the risk of bleeding and thromboembolic events in real-world patients with atrial fibrillation?
Does the choice of DOAC affect the risk of bleeding and thromboembolic events in real-world patients with atrial fibrillation?
In real-world patients with atrial fibrillation, apixaban demonstrates a more favorable safety profile regarding major and GI bleeding compared to rivaroxaban and dabigatran, while maintaining similar efficacy.
Answers are grounded in this paper and cite their sources.
Real-world data highlight differential bleeding risks among DOACs in AF; leaves open optimal agent selection pending randomized confirmation.
AIMS: To analyse the safety and efficacy of direct oral anticoagulants (DOACs) in real-world studies including atrial fibrillation (AF) patients. METHODS AND RESULTS: Systematic review and meta-analysis of observational studies including AF patients on DOACs. Primary endpoints: any, major, gastrointestinal (GI), intracranial haemorrhage (ICH), and haemorrhagic stroke (HS). Secondary endpoints: ischaemic stroke (IS), systemic embolism (SE), myocardial infarction (MI), and all-cause of death. A set of pair-wise meta-analyses using a random effect model and a random effect network meta-analysis under a Bayesian framework were performed. Prospero registration number: CRD42019137111. We included 21 studies with 605 771 AF patients. Apixaban was associated with lower major and GI bleeding compared with Rivaroxaban [hazard ratio (HR) 2.0, 95% confidence interval (CI) 1.6-2.5] and Dabigatran (HR 1.6, 95% CI 1.3-2.1). The latter drug performed better than Rivaroxaban (HR 1.2, 95% CI 1.0-1.5). Dabigatran and Apixaban had a similar association with HS, but Apixaban performed better than Rivaroxaban (HR 1.8, 95% CI 1.1-3.0). Apixaban had a similar association with Rivaroxaban and Dabigatran for ICH, the latter drug performing better than Rivaroxaban (HR 1.3, 95% CI 1.0-1.7). Rankograms showed that Apixaban was likely to be the first-choice treatment in relation to any (65%) major (100%) and GI bleeding (100%) followed by Dabigatran (46%, 100%, 99%, respectively). Dabigatran and Apixaban had similar rank as first choice for ICH (44% and 55%) and HS (52% and 48%). DOACs showed similar association with IS/SE, MI, all-cause of death. CONCLUSIONS: Analysis of real-world studies shows significant differences for safety among DOACs.
No takes yet. Share an insight, caveat, or question.
Menichelli et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: